1. Home
  2. MCHX vs ACOG Comparison

MCHX vs ACOG Comparison

Compare MCHX & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Marchex Inc. Class B

MCHX

Marchex Inc. Class B

HOLD

Current Price

$1.66

Market Cap

71.6M

ML Signal

HOLD

Logo Alpha Cognition Inc.

ACOG

Alpha Cognition Inc.

HOLD

Current Price

$6.25

Market Cap

115.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
MCHX
ACOG
Founded
2003
2000
Country
United States
Canada
Employees
N/A
N/A
Industry
Business Services
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
71.6M
115.5M
IPO Year
2004
N/A

Fundamental Metrics

Financial Performance
Metric
MCHX
ACOG
Price
$1.66
$6.25
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$18.00
AVG Volume (30 Days)
18.2K
102.3K
Earning Date
11-13-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$46,494,000.00
$7,427,199.00
Revenue This Year
N/A
N/A
Revenue Next Year
$6.70
$132.35
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.26
$3.75
52 Week High
$2.31
$11.54

Technical Indicators

Market Signals
Indicator
MCHX
ACOG
Relative Strength Index (RSI) 50.26 55.48
Support Level $1.60 $5.00
Resistance Level $1.75 $6.20
Average True Range (ATR) 0.07 0.55
MACD 0.01 0.08
Stochastic Oscillator 40.03 72.00

Price Performance

Historical Comparison
MCHX
ACOG

About MCHX Marchex Inc. Class B

Marchex Inc harnesses the power of AI and conversational intelligence to provide actionable insights aligned with prescriptive vertical market data analytics, driving operational excellence and revenue acceleration. Marchex enables executive, sales, and marketing teams to optimize customer journey experiences across communications channels, enabling enterprise strategies, empowering businesses to increase revenue through informed decision-making and strategic execution.

About ACOG Alpha Cognition Inc.

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

Share on Social Networks: